Clinical Study on Third-line Treatment of Advanced Duodenal Adenocarcinoma by Fuquinitinib Combined With Sindillimab

NCT05810142 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Third-line Treatment
Dvanced Duodenal Adenocarcinoma
Furquinelone Combined With Sintilimab

Interventions

DRUG: furquimatinib and sintilimab

Sponsor

RenJi Hospital